Key result
Lurasidone was associated with a lower risk of psychiatric hospitalization compared to olanzapine (olanzapine vs lurasidone OR 2.78; 95% CI 1.09-7.08; P=0.032), quetiapine, and risperidone.
Why the study?
Does lurasidone reduce psychiatric or all-cause hospitalization in adult patients with bipolar disorder compared to other atypical antipsychotics?
Observational (n=11,132)
Does lurasidone reduce psychiatric or all-cause hospitalization in adult patients with bipolar disorder compared to other atypical antipsychotics?
Odds Ratio: 2.78 (95% CI 1.09–7.08)
p-value: p=0.032
Lurasidone treatment in bipolar disorder is associated with a lower risk of psychiatric and all-cause hospitalizations compared to several other atypical antipsychotics.
Supports lurasidone preference in bipolar disorder to reduce hospitalizations; hypothesis-generating and requires RCTs before practice change.
OBJECTIVE: This observational study compared the risk of hospitalization for patients with bipolar disorder when treated with lurasidone versus other oral atypical antipsychotics. METHODS: This US commercial claims analysis (4 April 2010 through 24 September 2014) used the Optum Research Database to identify adult patients with bipolar disorder treated with oral atypical antipsychotics (N = 11,132). The first claim for an atypical antipsychotic defined the index date, with pre-index and post-index periods of 180 and 360 days, respectively. Every month of the post-index period was categorized as monotherapy treatment with lurasidone, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, no/minimal treatment or other. Starting with the initial month of treatment, the risk of psychiatric or all-cause hospitalization in the subsequent month was examined based on treatment in the current month and pre-index covariates (age, gender, hospitalizations, emergency room visits, diagnoses for anxiety, alcohol abuse, substance abuse, hypertension, type 2 diabetes and obesity) and time-varying versions of the pre-index covariates using a marginal structural model. RESULTS: After controlling for covariates, relative to lurasidone, the odds of psychiatric and all-cause hospitalization, respectively, were 2-3 times higher for olanzapine (odds ratio [OR] = 2.78, CI 1.09, 7.08, p = .032; OR = 3.20, CI 1.24, 8.26, p = .016), quetiapine (OR = 2.80, CI 1.13, 6.95, p = .026; OR = 3.23, CI 1.29, 8.11, p = .013), risperidone (OR = 2.50, CI 1.01, 6.21, p = .048; OR = 2.79, CI 1.11, 7.02, p = .029), aripiprazole (OR = 2.13, CI 0.87, 5.20, p = .097; OR = 2.57, CI 1.04, 6.37, p = .041) and ziprasidone (OR =2.31, CI 0.91, 5.85, p = .079; OR = 2.49, CI 0.97, 6.40, p = .058). CONCLUSIONS: In this claims database analysis, lurasidone-treated patients with bipolar disorder had a significantly lower risk of psychiatric hospitalization compared to quetiapine, olanzapine and risperidone, but not aripiprazole or ziprasidone. Lurasidone-treated patients had a significantly lower risk of all-cause hospitalization compared to quetiapine, olanzapine, risperidone and aripiprazole, but not ziprasidone.
No takes yet. Share an insight, caveat, or question.
Ng‐Mak et al. (2018) conducted an observational in Bipolar disorder (n=11,132). Lurasidone vs. Other oral atypical antipsychotics (olanzapine, quetiapine, risperidone, aripiprazole, ziprasidone) was evaluated on Psychiatric hospitalization (OR 2.78, 95% CI 1.09-7.08, p=0.032). Lurasidone was associated with a lower risk of psychiatric hospitalization compared to olanzapine (olanzapine vs lurasidone OR 2.78; 95% CI 1.09-7.08; P=0.032), quetiapine, and risperidone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: